BiomX subsidiary BiomX Ltd files for insolvency; Phase 2b study discontinued

BiomX Inc.

Phase 2b study discontinued Dec 8 due to resource constraints exceeding available funds.
Dec 11: Board of BiomX Ltd authorized filing for insolvency proceedings in Israel.
Company evaluating strategic options; continues BX011 program via Adaptive Phage Therapeutics.
Limited financial resources cited as primary reason for study discontinuation and insolvency filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.